Clinical trials: Epithelial Mesothelioma
Mesothelioma
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
The aim of this study is to learn about how mesothelioma affects patients' emotional and physical well-being. Also, the investigators would like to learn more about what patients need and how they deal with this illness.
- Trial name
- NCT01356251
- Testing
- Questionnaires & online virtual support group
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mesothelioma, Lung Cancer
Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)
The goal of this study is to assess the efficacy and safety of an oral investigational drug suberoylanilide hydroxamic acid (vorinostat, MK-0683) compared to placebo, in the treatment of participants with advanced malignant…
- Trial name
- NCT00128102
- Testing
- Vorinostat
- Volunteers
- 661 people
- Sponsor
- Merck Sharp & Dohme LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
This is an open-label, non-randomized, multicenter, translational Phase 1/2 dose-escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor…
- Conditions
- Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural
- Trial name
- NCT05278975
- Testing
- RSO-021
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- RS Oncology LLC
Mesothelioma
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
The sponsor raise the hypothesis that inhibition of immune PD-1+/- CTLA-4 check-point(s) would delay tumor progression in patients with unresectable MPM, experiencing disease progression after one or two lines of chemotherapy…
- Trial name
- MAPS2 (NCT02716272)
- Testing
- Nivolumab, Nivolumab + Ipilimumab
- Where
- 22 sites in France
- Volunteers
- 125 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Cancer
A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.
Multicenter, open phase 2 study on patients with malignant mesothelioma. Standardly, 4 to 6 cycles of palliative chemotherapy, platinum in combination with pemetrexed, are given.
- Trial name
- MesoMab (NCT00996567)
- Testing
- Cetuximab (Erbitux)
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 22 people
- Sponsor
- University Hospital, Ghent
Solid Tumor
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in participants with wild-type TP53 advanced solid tumors.
- Trial name
- NCT03975387
- Testing
- ASTX295
- Where
- 11 sites in United States
- Volunteers
- 106 people
- Sponsor
- Taiho Oncology, Inc.
Pleural Effusion, Malignant, Pleural Mesothelioma
A Comparative Study Between Regional Anesthesia in Thoracoscopes and the Conventional General Anesthesia
Video-assisted thoracic surgery (VATS) is usually performed with general anesthesia and single lung ventilation. However, performing thoracic surgery under awake regional anesthesia has several potential advantages including…
- Conditions
- Pleural Effusion, Malignant, Pleural Mesothelioma, Pleural Empyema, Pulmonary Diseases or Conditions
- Trial name
- VATS (NCT05077111)
- Testing
- Thoracic Epidural Anesthesia, General Anesthesia with One Lung Ventilation
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mohamed Reda Ashour
Clinical Trial, Phase I, Neuroendocrine Tumors
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
This is a phase I study of 177Lu-DOTA-TATE in combination with the PARP-inhibitor olaparib for treatment of patients with somatostatin receptor positive tumours detected by 68Ga-DOTA-TATE/TOC PET.
- Conditions
- Clinical Trial, Phase I, Neuroendocrine Tumors, Thymoma, Mesothelioma
- Trial name
- LuPARP (NCT04375267)
- Testing
- 177Lu-DOTA-TATE + olaparib
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Vastra Gotaland Region
Breast Cancer, Colorectal Cancer
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
RATIONALE: Sorafenib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00703638
- Testing
- cisplatin, pemetrexed disodium, sorafenib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non-Small Cell Lung Cancer, Metastatic Melanoma
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
The aims of this Study were to determine: How much of the Study Drug (bemcentinib) ends up in urine and faeces How much of the Study Drug and its breakdown products get into the bloodstream The breakdown products (metabolites) of…
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- 8479217 (NCT06469138)
- Testing
- Bemcentinib
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- BerGenBio ASA
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Malignant Mesothelioma
S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003723
- Testing
- gemcitabine hydrochloride
- Where
- 84 sites in United States
- Volunteers
- 57 people
- Sponsor
- SWOG Cancer Research Network
Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
Meso-Immune is a retrospective study to assess the efficacy and safety of the combination of Nivolumab and Ipilimumab used in first-line treatment of adult patients with unresectable Malignant Pleural Mesothelioma (MPM).
- Trial name
- MESO-IMMUNE (NCT05308966)
- Testing
- Data collection
- Where
- 63 sites in France
- Volunteers
- 204 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
Background: A germline mutation is a change to a person s genes that is carried through their DNA. These mutations can be passed on from parents to their offspring.
- Conditions
- Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations, Tumor Predisposition Syndrome (TPDS), Mesothelioma
- Trial name
- NCT04431024
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Malignant Pleural Disease, Mesothelioma
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
The purpose of this Phase I study is to test the safety of different doses of specially prepared immune cells (called "T cells") collected from blood.
- Conditions
- Malignant Pleural Disease, Mesothelioma, Metastases, Lung Cancer
- Trial name
- NCT02414269
- Testing
- iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 113 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Pleural Mesothelioma, Trapped Lung
MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.
Malignant pleural mesothelioma is a cancer, caused by asbestos, which currently affects 2500 people in the UK each year. The main symptom is breathlessness caused by fluid building up in the space between the lung and the chest…
- Trial name
- MesoTRAP (NCT03412357)
- Testing
- pleurectomy/decortication, indwelling pleural catheter
- Where
- 18 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Mesothelioma
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, gemcitabine, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00101283
- Testing
- pemetrexed disodium, gemcitabine hydrochloride, carboplatin
- Where
- 115 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eastern Cooperative Oncology Group
Malignant Pleural Mesothelioma
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
The purpose of this study is to find out whether IMPRINT in combination with pembrolizumab is a safe treatment for people with malignant pleural mesothelioma (MPM).The highest dose of IMPRINT that causes few or mild side effects…
- Trial name
- NCT04897022
- Testing
- Pembrolizumab, IMPRINT
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Mesothelioma
Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- ALIMESO (NCT00541073)
- Testing
- vitamin B12, cisplatin, pemetrexed disodium
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Oscar Lambret
Mesothelioma
New Preclinical and Clinical Approaches to Mesothelioma
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis.
- Trial name
- NCT06536179
- Where
- 2 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Marco Emilio Bianchi